Applied Therapeutics Logo

Great News From HNF TRIAD Industry Partner — Applied Therapeutics

by | Aug 2, 2023 | 0 comments

Applied Therapeutics, Inc. has announced that their drug candidate, AT-007 (Govorestat), has received orphan medicinal product designation from the European Medicines Agency (EMA) for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency. This designation reflects the high unmet medical need in SORD Deficiency and recognizes the benefit of Govorestat in reducing toxic sorbitol levels. New data published in the Journal of Clinical Investigation has further explained the molecular pathophysiology of SORD neuropathy and the role of sorbitol in neuronal toxicity. This is an important step for advancing regulatory initiatives in Europe and provides certain benefits and incentives for the development and marketing of the medicine.

Learn more on this topic

Related Blog Posts

HNF is Reshaping Drug Repurposing for CMT

HNF is Reshaping Drug Repurposing for CMT

HNF has partnered with Rarebase, a public benefit precision medicine company that has screened a large library of FDA approved small molecules to identify candidates for various types of CMT. Their tech-enabled drug discovery platform is called Function™. There are many published discoveries on the genetic cause of many types of CMT, including an understanding of the basic mechanism of disease and potential targets for FDA-approved drug repurposing. It is this understanding that allows HNF and Rarebase to target the genetic root cause of CMT.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news